1
|
Fowkes A, Foster R, Kane S, Thresher A, Werner AL, de Oliveira AAF. Enhancing global and local decision making for chemical safety assessments through increasing the availability of data. Toxicol Mech Methods 2023:1-12. [PMID: 36600456 DOI: 10.1080/15376516.2022.2156007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Toxicity safety assessments are a fundamental part of the lifecycle of products and aim to protect human health and the environment from harmful exposures to chemical substances. To make decisions regarding the suitability of testing strategies, the applicability of individual tests or concluding an assessment for an individual chemical requires data. This review outlines how different forms of data sharing, from enhancing publicly-available data to extracting knowledge from commercially-sensitive data, leads to increased quantity and quality of evidence being available for safety assessors to review. This can result in more confident decisions for different use cases in the context of chemical safety assessments. Although a number of challenges remain with progressing the evolution of toxicity safety assessments, data sharing should be considered as a key approach to accelerating the development and uptake of new best practices.
Collapse
|
2
|
Haverić A, Durmić-Pašić A, Alić A, Mujezinović I, Smajlović A, Ostojić J, Ahatović A, Hadžić M, Prašović S, Haverić S, Galić B. Biochemical and histomorphological findings in Swiss Wistar rats treated with potential boron-containing therapeutic - K2[B3O3F4OH]. J Trace Elem Med Biol 2020; 62:126642. [PMID: 32950859 DOI: 10.1016/j.jtemb.2020.126642] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/15/2020] [Revised: 08/10/2020] [Accepted: 08/31/2020] [Indexed: 11/28/2022]
Abstract
BACKGROUND Boron and boron containing compounds are known for their biological and protective roles being non-toxic and non-mutagenic in low concentrations. Male rats were exposed to halogenated boroxine (HB), dipotassium-trioxohydroxytetrafluorotriborate K2[B3O3F4OH], a potential new boron-containing therapeutic, aiming to determine concentrations with no adverse effects on selected serum biochemical parameters and histomorphological features. METHODS HB was prepared by reacting potassium hydrofluoride (KHF2) with boric acid in molar ratios 2:3 at room temperature and its primary structure contains 4 fluorine atoms substituted in 6-membered ring. In concentrations of 10, 25, 35 and 45 mg/kg, HB was administered intraperitoneally as a single dose. Biochemical parameters were observed 24 and 96 h following the treatment. Effects of HB on biochemical blood parameters were also observed 24 h following continuous nine days application in concentrations of 10 mg/kg intraperitoneally and 50 mg/kg per os. Histomorphological observation of kidneys, liver, spleen, lungs and heart was performed for all treated animals. RESULTS Administration of single high dose of HB (35 mg/kg-45 mg/kg) effected high levels of urea and creatinine, which indicated renal injury that appeared to be temporary. Possible cause of concern is pancreatic injury indicated by elevated levels of serum amylase in the groups of animals that received the highest dosages of the substance. Histopathological examination of selected tissues revealed mild to moderate lesions in the kidneys and livers associated with administration of HB. CONCLUSION Observation of biochemical serum parameters or histopathology of examined tissues revealed no adverse effects of HB either after the administration of single dose lower than 35 mg/kg or following repeated administration at 10 mg/kg. These dosages should be further considered for potential therapeutic applications.
Collapse
Affiliation(s)
- Anja Haverić
- Institute for Genetic Engineering and Biotechnology, Laboratory for Cytogenetics and Genotoxicology, University of Sarajevo, Zmaja od Bosne 8, 71 000 Sarajevo, Bosnia and Herzegovina.
| | - Adaleta Durmić-Pašić
- Institute for Genetic Engineering and Biotechnology, Laboratory for Cytogenetics and Genotoxicology, University of Sarajevo, Zmaja od Bosne 8, 71 000 Sarajevo, Bosnia and Herzegovina
| | - Amer Alić
- Veterinary Faculty, University of Sarajevo, Department of Pathology and Department of Pharmacology and Toxicology, Zmaja od Bosne 90, 71 000 Sarajevo, Bosnia and Herzegovina
| | - Indira Mujezinović
- Veterinary Faculty, University of Sarajevo, Department of Pathology and Department of Pharmacology and Toxicology, Zmaja od Bosne 90, 71 000 Sarajevo, Bosnia and Herzegovina
| | - Ahmed Smajlović
- Veterinary Faculty, University of Sarajevo, Department of Pathology and Department of Pharmacology and Toxicology, Zmaja od Bosne 90, 71 000 Sarajevo, Bosnia and Herzegovina
| | - Jelena Ostojić
- Faculty of Science, Department of Chemistry, University of Sarajevo, Zmaja od Bosne 35, 71 000 Sarajevo, Bosnia and Herzegovina
| | - Anesa Ahatović
- Institute for Genetic Engineering and Biotechnology, Laboratory for Cytogenetics and Genotoxicology, University of Sarajevo, Zmaja od Bosne 8, 71 000 Sarajevo, Bosnia and Herzegovina
| | - Maida Hadžić
- Institute for Genetic Engineering and Biotechnology, Laboratory for Cytogenetics and Genotoxicology, University of Sarajevo, Zmaja od Bosne 8, 71 000 Sarajevo, Bosnia and Herzegovina
| | - Senad Prašović
- Veterinary Faculty, University of Sarajevo, Department of Pathology and Department of Pharmacology and Toxicology, Zmaja od Bosne 90, 71 000 Sarajevo, Bosnia and Herzegovina
| | - Sanin Haverić
- Institute for Genetic Engineering and Biotechnology, Laboratory for Cytogenetics and Genotoxicology, University of Sarajevo, Zmaja od Bosne 8, 71 000 Sarajevo, Bosnia and Herzegovina
| | - Borivoj Galić
- Faculty of Science, Department of Chemistry, University of Sarajevo, Zmaja od Bosne 35, 71 000 Sarajevo, Bosnia and Herzegovina
| |
Collapse
|
3
|
Masuda-Herrera MJ, Dobo KL, Kenyon MO, Kenny JD, Galloway SM, Escobar PA, Reddy MV, Jolly RA, Trejo-Martin A, Brown C, Mckeon M, Young M, Bruce S, Pant K, Dutta A, Kulkarni R, Bercu JP. In Vivo Mutagenicity Testing of Arylboronic Acids and Esters. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 2019; 60:766-777. [PMID: 31335992 DOI: 10.1002/em.22320] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/25/2019] [Revised: 07/09/2019] [Accepted: 07/15/2019] [Indexed: 06/10/2023]
Abstract
Arylboronic acids and esters (referred to collectively as arylboronic compounds) are commonly used intermediates in the synthesis of pharmaceuticals but pose a challenge for chemical syntheses because they are often positive for bacterial mutagenicity in vitro. As such, arylboronic compounds are then typically controlled to levels that are acceptable for mutagenic impurities, that is, the threshold of toxicological concern (TTC). This study used ICH M7 guidance to design and conduct a testing strategy to investigate the in vivo relevance of the in vitro positive findings of arylboronic compounds. Eight arylboronic compounds representing a variety of chemical scaffolds were tested in Sprague Dawley and/or Wistar rats in the in vivo Pig-a (peripheral blood reticulocytes and mature red blood cells) and/or comet assays (duodenum and/or liver). Five of the eight compounds were also tested in the micronucleus (peripheral blood) assay. The arylboronic compounds tested orally demonstrated high systemic exposure; thus the blood and bone marrow were adequately exposed to test article. One compound was administered intravenously due to formulation stability issues. This investigation showed that arylboronic compounds that were mutagenic in vitro were not found to be mutagenic in the corresponding in vivo assays. Therefore, arylboronic compounds similar to the scaffolds tested in this article may be considered non-mutagenic and managed in accordance with the ICH Q3A/Q3B guidelines. Environ. Mol. Mutagen. 2019. © 2019 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
| | - Krista L Dobo
- Pfizer Global Research & Development, Groton, Connecticut, 06340
| | | | - Julia D Kenny
- GlaxoSmithKline, Hertfordshire, SG12 0DP, United Kingdom
| | | | | | | | - Robert A Jolly
- Toxicology Division, Eli Lilly and Company, Indianapolis, Indiana
| | | | - Caren Brown
- MilliporeSigma BioReliance® Toxicology Services, Rockville, Maryland
| | - Marie Mckeon
- MilliporeSigma BioReliance® Toxicology Services, Rockville, Maryland
| | - Megan Young
- MilliporeSigma BioReliance® Toxicology Services, Rockville, Maryland
| | - Shannon Bruce
- MilliporeSigma BioReliance® Toxicology Services, Rockville, Maryland
| | - Kamala Pant
- MilliporeSigma BioReliance® Toxicology Services, Rockville, Maryland
| | - Aparajita Dutta
- MilliporeSigma BioReliance® Toxicology Services, Rockville, Maryland
| | - Rohan Kulkarni
- MilliporeSigma BioReliance® Toxicology Services, Rockville, Maryland
| | | |
Collapse
|
4
|
Teasdale A, Elder DP. Analytical control strategies for mutagenic impurities: Current challenges and future opportunities? Trends Analyt Chem 2018. [DOI: 10.1016/j.trac.2017.10.027] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
|
5
|
Farfán-García ED, Castillo-Mendieta NT, Ciprés-Flores FJ, Padilla-Martínez II, Trujillo-Ferrara JG, Soriano-Ursúa MA. Current data regarding the structure-toxicity relationship of boron-containing compounds. Toxicol Lett 2016; 258:115-125. [PMID: 27329537 DOI: 10.1016/j.toxlet.2016.06.018] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2016] [Revised: 05/29/2016] [Accepted: 06/17/2016] [Indexed: 02/07/2023]
Abstract
Boron is ubiquitous in nature, being an essential element of diverse cells. As a result, humans have had contact with boron containing compounds (BCCs) for a long time. During the 20th century, BCCs were developed as antiseptics, antibiotics, cosmetics and insecticides. Boric acid was freely used in the nosocomial environment as an antiseptic and sedative salt, leading to the death of patients and an important discovery about its critical toxicology for humans. Since then the many toxicological studies done in relation to BCCs have helped to establish the proper limits of their use. During the last 15 years, there has been a boom of research on the design and use of new, potent and efficient boron containing drugs, finding that the addition of boron to some known drugs increases their affinity and selectivity. This mini-review summarizes two aspects of BCCs: toxicological data found with experimental models, and the scarce but increasing data about the structure-activity relationship for toxicity and therapeutic use. As is the case with boron-free compounds, the biological activity of BCCs is related to their chemical structure. We discuss the use of new technology to discover potent and efficient BCCs for medicinal therapy by avoiding toxic effects.
Collapse
Affiliation(s)
- E D Farfán-García
- Departamento de Bioquímica, Sección de Estudios de Posgrado e Investigación. Escuela Superior de Medicina, Instituto Politécnico Nacional. Plan de San Luis y Díaz Mirón, 11340, México City, México; Departamento de Fisiología, Sección de Estudios de Posgrado e Investigación. Escuela Superior de Medicina, Instituto Politécnico Nacional. Plan de San Luis y Díaz Mirón, 11340, México City, México
| | - N T Castillo-Mendieta
- Departamento de Fisiología, Sección de Estudios de Posgrado e Investigación. Escuela Superior de Medicina, Instituto Politécnico Nacional. Plan de San Luis y Díaz Mirón, 11340, México City, México
| | - F J Ciprés-Flores
- Departamento de Bioquímica, Sección de Estudios de Posgrado e Investigación. Escuela Superior de Medicina, Instituto Politécnico Nacional. Plan de San Luis y Díaz Mirón, 11340, México City, México; Departamento de Fisiología, Sección de Estudios de Posgrado e Investigación. Escuela Superior de Medicina, Instituto Politécnico Nacional. Plan de San Luis y Díaz Mirón, 11340, México City, México
| | - I I Padilla-Martínez
- Unidad Profesional Interdisciplinaria de Biotecnología, Instituto Politécnico Nacional, Avenida Acueducto s/n, Barrio La Laguna Ticomán, 07340, México
| | - J G Trujillo-Ferrara
- Departamento de Bioquímica, Sección de Estudios de Posgrado e Investigación. Escuela Superior de Medicina, Instituto Politécnico Nacional. Plan de San Luis y Díaz Mirón, 11340, México City, México
| | - M A Soriano-Ursúa
- Departamento de Fisiología, Sección de Estudios de Posgrado e Investigación. Escuela Superior de Medicina, Instituto Politécnico Nacional. Plan de San Luis y Díaz Mirón, 11340, México City, México.
| |
Collapse
|
6
|
Briggs KA. Is preclinical data sharing the new norm? Drug Discov Today 2016; 23:499-502. [PMID: 27173642 DOI: 10.1016/j.drudis.2016.05.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2015] [Revised: 04/04/2016] [Accepted: 05/04/2016] [Indexed: 11/16/2022]
Abstract
Is preclinical data sharing the new norm? In my experience, it is certainly becoming more commonplace. However, it is not yet standard practice and remains the preserve of special projects. Here, I expound the benefits of sharing proprietary preclinical data using examples of successful initiatives. The main barriers to data sharing are then described, with suggestions for how these might be overcome. To maximise the benefits and minimise the risks involved, I suggest that organisations look to develop standard operating procedures for data sharing.
Collapse
|